Neurocrine Biosciences Inc (NBIX)
96.03
+1.72 +1.82%
NASDAQ
Apr 8, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 788.09M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 0.33 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 37.01M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 98.99% |
| Profit Margin (Quarterly) | 13.93% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 8.863B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 11.55 |
| PE Ratio | 291.00 |
| Price to Book Value | 13.92 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.6418 |
| Free Cash Flow (Quarterly) | 99.74M |
| Return on Equity | Upgrade |
View All NBIX News
News
-
WireHeadlineTime (ET)
-
MT Newswires04/03 10:16
-
MT Newswires04/03 10:06
-
SA Breaking News04/03 08:54
-
SA Breaking News04/03 08:54
-
PR Newswire04/03 08:30
-
Yahoo03/30 18:06
-
Yahoo03/27 12:45
-
Yahoo03/26 11:40
-
SA Breaking News03/25 13:54
-
Yahoo03/18 14:29
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 04/29/2020 16:30 EDT | Misc | Neurocrine Biosciences Inc First Quarter Earnings Conference Call in 2020 |
| 04/29/2020 | Earnings | Neurocrine Biosciences Inc First Quarter Earnings in 2020 Release |
| 02/07/2020 | Misc | Neurocrine Biosciences Inc Annual Report for 2019 |
| 02/04/2020 16:30 EST | Misc | Neurocrine Biosciences Inc Fourth Quarter Earnings Conference Call for 2019 |
| 02/04/2020 | Earnings | Neurocrine Biosciences Inc Fourth Quarter Earnings in 2019 Release |
| 11/04/2019 16:30 EST | Misc | Neurocrine Biosciences Inc Third Quarter Earnings Conference Call for 2019 |
| 11/04/2019 | Earnings | Neurocrine Biosciences Inc Third Quarter Earnings in 2019 Release |
| 07/29/2019 16:30 EDT | Misc | Neurocrine Biosciences Inc Second Quarter Earnings Conference Call in 2019 |
| 07/29/2019 | Earnings | Neurocrine Biosciences Inc Second Quarter Earnings in 2019 Release |
| 05/22/2019 | Misc | Neurocrine Biosciences Inc Annual General Meeting in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.neurocrine.com
- Investor Relations URL: http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-news&nyo=0
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Apr. 29, 2020
- Last Earnings Release: Feb. 04, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Dec. 29, 1995
- Description: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 96.03 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| PBE | Invesco Dynamic Biotech & Genome ETF | 5.38% |
| PBE | Invesco Dynamic Biotech & Genome ETF | 5.38% |
| DYN1651 | Dynamic Power American Growth Series U | 3.90% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.35% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.35% |
| FIJYX | Fidelity Advisor® Biotechnology Z | 2.53% |
| JFNSX | Janus Henderson Global Life Sciences S | 1.95% |
| JCNRX | Janus Henderson Contrarian R | 1.92% |
| XBI | SPDR® S&P Biotech ETF | 1.81% |
| XBI | SPDR® S&P Biotech ETF | 1.81% |
| FBIOX | Fidelity® Select Biotechnology | 1.56% |
| HQH | Tekla Healthcare Investors | 1.20% |
| IBB | iShares Nasdaq Biotechnology ETF | 1.17% |
| IBB | iShares Nasdaq Biotechnology ETF | 1.17% |
| VISGX | Vanguard Small Cap Growth Index Inv | 0.54% |
| VBK | Vanguard Small-Cap Growth ETF | 0.54% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- NBIX Tweets Stocktwits
Advertisement
